Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer | Zendy

Steven I. Sherman | Zendy; Lori J. Wirth | Zendy; Jean-Pierre Droz | Zendy; Michael Hofmann | Zendy; Lars Bastholt | Zendy; Renato Martins | Zendy; Lisa Licitra | Zendy; Michael Eschenberg | Zendy; Yu-Nien Sun | Zendy; Todd Juan | Zendy; Daniel E. Stepan | Zendy; Martin Schlumberger | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

Author(s) -

Steven I. Sherman,

Lori J. Wirth,

Jean-Pierre Droz,

Michael Hofmann,

Lars Bastholt,

Renato Martins,

Lisa Licitra,

Michael Eschenberg,

Yu-Nien Sun,

Todd Juan,

Daniel E. Stepan,

Martin Schlumberger

Publication year - 2008

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa075853

Subject(s) - medicine , thyroid cancer , thyroglobulin , gastroenterology , progressive disease , papillary thyroid cancer , thyroid carcinoma , cancer , thyroid , response evaluation criteria in solid tumors , endocrinology , surgery , oncology , disease

The expression of vascular endothelial growth factor (VEGF) is characteristic of differentiated thyroid cancer and is associated with aggressive tumor behavior and a poor clinical outcome. Motesanib diphosphate (AMG 706) is a novel oral inhibitor of VEGF receptors, platelet-derived growth-factor receptor, and KIT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research